Revelation Biosciences (FRA:56U0) Short-Term Capital Lease Obligation : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Short-Term Capital Lease Obligation?

Revelation Biosciences's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil.

Revelation Biosciences's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€0.02 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Revelation Biosciences Short-Term Capital Lease Obligation Historical Data

The historical data trend for Revelation Biosciences's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Short-Term Capital Lease Obligation Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.02

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial								-	-	-	-	-

Revelation Biosciences Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Revelation Biosciences Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines